Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in immuno research, from the discovery & development of cell & antibody therapies through to omics-based approaches and clinical case studies

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Therapeutic Modalities

SomaSignal® Tests

Multiple clinical assessments from a single blood draw.
Read More
Therapeutic Modalities

SomaScan Assay

A proteomics platform driving pioneering discoveries
Read More
Therapeutic Modalities

Enfortumab Vedotin/Pembrolizumab Combo Beats Chemo in Phase III Breakthrough

The Phase III clinical trial, named EV-302/KEYNOTE-A39, has unveiled that immunotherapy can outperform chemo in urothelial bladder cancer for the first time.
Read More
Therapeutic Modalities

Compugen: Exploring New Pathways and Combinations in Immunotherapy

Looking at new pathways for ICIs and Compugen's triple pathway hypothesis may be paving the way for next-generation cancer immunotherapy.
Read More
Therapeutic Modalities

European Commission Approves Genmab’s Subcutaneous Bispecific Antibody Tepkinly

The approval follows positive results from Genmab's 'Epcore' phase I/II clinical trial.
Read More
Therapeutic Modalities

NK Cell Therapies: Development, Application, and Challenges

Sourcing NK cells, expansion techniques, gene modification, quality control, safety, preservation, and delivery.
Read More
Therapeutic Modalities

Another Partnership from Takeda and F-Star Therapeutics to Look for Antibody-Based Therapies

The collaboration includes an upfront payment, milestone-dependent funds, and commercial royalties for F-star.
Read More
Therapeutic Modalities

Immune Cell Types: Their Opportunities for Therapeutic Use in Oncology

An introduction to the various cell types in the immune system and the opportunities to harness them in immuno-oncology therapies.
Read More
Therapeutic Modalities

William Coley, the Father of Cancer Immunotherapy and His Legacy

Despite facing criticism in his time, his work laid the foundation for modern immuno-oncology and his legacy continues through the Cancer Research Institute.
Read More
Therapeutic Modalities

AstraZeneca and Daiichi Sankyo Share Results of IO Combination Therapy in Ib Clinical Trial

Preliminary results from phase Ib clinical trial, TROPION-Lung02, evaluating the antibody drug conjugate datopotamab deruxtecan in combination with pembrolizumab.
Read More
Therapeutic Modalities

Monoclonal Antibodies: Guided Missiles in the Battle Against Cancer and More

Monoclonal antibodies (mAbs) have emerged as highly promising and versatile treatments for various diseases, particularly cancer.
Read More
Therapeutic Modalities

Identifying highly potent TNF-?-secreting T cells from blood samples in 7 hours using the Xdrop® double-emulsion droplet-based workflow

Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop workflow reveals highly potent TNF-?-secreting T cells in a human blood sample.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things immuno